-term survival after pulmonary resection for small cell carcinoma of the lung [comment] . Thorax 1989 ; 44 : 784 – 787 . 11 Shah SS Thompson J Goldstraw P . Results of operation without adjuvant therapy in the treatment of small cell lung cancer
Search Results
Alyssa G. Rieber and Richard L. Theriault
. Lancet 2005 ; 365 : 60 – 62 . 16 Winer EP Hudis C Burstein HJ . American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast
Margaret Tempero
landmark studies, such as those that defined adjuvant therapy in breast and colorectal cancers, two of the biggest success stories. So my answer to the title question is “yes,” we need a publicly funded clinical trials network. The pharmaceutical industry
Katya Losk, Ines Vaz-Luis, Kristen Camuso, Rafael Batista, Max Lloyd, Mustafa Tukenmez, Mehra Golshan, Nancy U. Lin, and Craig A. Bunnell
In an era of increasing use of Oncotype DX to assist with chemotherapy treatment decisions, an aging population with comorbidities needing to be addressed, and the more prevalent use of MIR, it is not surprising that wait times to adjuvant therapy
David H. Moore
with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix . J Clin Oncol 2000 ; 18 : 1606 – 1613 . 27 Clinical Announcement . National Cancer Institute. Concurrent
Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Susana M. Campos, Kathleen R. Cho, Hye Sook Chon, Christina Chu, David Cohn, Marta Ann Crispens, Don S. Dizon, Oliver Dorigo, Patricia J. Eifel, Christine M. Fisher, Peter Frederick, David K. Gaffney, Ernest Han, Susan Higgins, Warner K. Huh, John R. Lurain III, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Todd Tillmanns, Stefanie Ueda, Fidel A. Valea, Emily Wyse, Catheryn M. Yashar, Nicole McMillian, and Jillian Scavone
has shifted from radical approaches to more conservative surgery with the addition of RT or chemoradiation. 15 Because the data are limited, trials are ongoing to identify optimal approaches for neoadjuvant and adjuvant therapy, which may include
Frank Balis, Daniel M. Green, Clarke Anderson, Shelly Cook, Jasreman Dhillon, Kenneth Gow, Susan Hiniker, Rama Jasty-Rao, Chi Lin, Harold Lovvorn III, Iain MacEwan, Julian Martinez-Agosto, Elizabeth Mullen, Erin S. Murphy, Mark Ranalli, Daniel Rhee, Denise Rokitka, Elisabeth (Lisa) Tracy, Tamara Vern-Gross, Michael F. Walsh, Amy Walz, Jonathan Wickiser, Matthew Zapala, Ryan A. Berardi, and Miranda Hughes
those who are initially unresectable, or those with bilateral or metastatic disease. Risk assessment is done to determine the need for and type of adjuvant therapy after surgery (see Risk Assessment for FHWT [WILMS-F] in the algorithm). 10 , 64 Most
D. Craig Allred, Robert W. Carlson, Donald A. Berry, Harold J. Burstein, Stephen B. Edge, Lori J. Goldstein, Allen Gown, M. Elizabeth Hammond, James Dirk Iglehart, Susan Moench, Lori J. Pierce, Peter Ravdin, Stuart J. Schnitt, and Antonio C. Wolff
progesterone receptors in the treatment of breast cancer . Cancer 1980 ; 46 ( 12 Suppl ): 2884 – 2888 . 5 Viale G Regan MM Maiorano E . Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of
Ali A. Mokdad, Rebecca M. Minter, Adam C. Yopp, Matthew R. Porembka, Sam C. Wang, Hong Zhu, Mathew M. Augustine, John C. Mansour, Michael A. Choti, and Patricio M. Polanco
between preoperative CT and CRT despite more favorable postoperative pathologic findings with CRT. Our results also suggest higher postoperative morbidity and mortality and lower delivery rates of postoperative adjuvant therapy associated with preoperative
Andrea Cercek, Karyn A. Goodman, Carla Hajj, Emily Weisberger, Neil H. Segal, Diane L. Reidy-Lagunes, Zsofia K. Stadler, Abraham J. Wu, Martin R. Weiser, Philip B. Paty, Jose G. Guillem, Garrett M. Nash, Larissa K. Temple, Julio Garcia-Aguilar, and Leonard B. Saltz
complete response; TME, total mesorectal excision. Historically, one of the major shortfalls of adjuvant therapy is that many eligible patients, ranging from 17% to 28% in various trials, either do not start postoperative chemotherapy or initiate
